Saturday 17 October 2026
Export CNTX’s income statement to Excel — free account
Context Therapeutics Inc.
CNTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 66.7% and free cash flow fell 20.6%, each against the same quarter a year earlier.
0.24
0.00
0.00%
Follow CNTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(33.68%) | (46.39%) | (56.19%) | (76.14%) | |
| (31.94%) | (43.36%) | (52.99%) | (68.96%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(36.19%) | (59.84%) | (77.29%) | (120.91%) | |
Free Cash Flow per Share |
(0.24) | (0.28) | (0.34) | (0.36) | |
Free Cash Flow |
(22.38) | (26.42) | (32.82) | (34.03) | |
Capital Expenditures |
(0.03) | (0.03) | (0.04) | (0.06) | |
| Other line items | |||||
Cash ROIC |
(14.91%) | (20.89%) | (30.75%) | (41.92%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.85 | 0.73 | 0.82 | 0.74 | |
Depreciation/Fixed assets |
0.45 | 0.55 | 0.27 | 0.26 | |
Capex/Depreciation |
(2.23) | (2.08) | (2.21) | (2.86) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.23) | (0.28) | (0.34) | (0.36) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates